Delgocitinib for treating moderate to severe chronic hand eczema (TA1107)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 November 2025
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Delgocitinib for Chronic Hand Eczema [ID6688]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC